<DOC>
	<DOCNO>NCT01101295</DOCNO>
	<brief_summary>The primary purpose study describe prospective observational study serious adverse event occur patient treat off-label rituximab Immune Thrombocytopenia .</brief_summary>
	<brief_title>The ITP-RITUX Cohort : Rituximab Immune ThrombocytoPenia .</brief_title>
	<detailed_description>Rituximab ( RTX ) use treatment malignant non-Hodgkin 's indication authorize since 1997 consider effective well tolerate . Rituximab also effective well tolerate combination methotrexate severe rheumatoid arthritis ( RA ) refractory anti-TNF . To date , RA autoimmune disease rituximab proven efficacy randomized trial obtain authorization indication . There also data literature , benefit rituximab autoimmune disease like Lupus , cryoglobulinemia associate Hepatitis C Sjogren 's disease . Immune Thrombocytopenia ( ITP ) autoimmune disease thrombocytopenia due part destruction platelets autoantibody . In adult , disease often chronic severe form , treatment choice splenectomy . Rituximab suggest chronic ITP use 4 weekly infusion 375 mg/m2 , 60 % patient achieve immediate response 30 40 % prolonged response . These encouraging result apparent good tolerance advocate use rituximab first-line treatment patient refractory splenectomy . In France , Afssaps - French Health Products Safety Agency recently issue temporary protocol processing authorize rituximab indication . Nevertheless , many question remain unresolved , include tolerance long-term treatment risk late relapse responder . This justify creation register , whose establishment recommend Afssaps - French Health Products Safety Agency .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>ITP diagnosis accord American Society Hematology society Secondary ITP underlie disease autoimmune disease ( Lupus , Sjogren.. ) Previous treatment rituximab Secondary ITP associate hematologic disease ( Chronic Lymphocytic Leukemia , Hodgkin Disease ... ) Secondary ITP associate chronic infectious disease ( Hepatitis B , C , HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Immune Thrombocytopenia</keyword>
	<keyword>Rituximab</keyword>
	<keyword>side effect</keyword>
	<keyword>tolerance</keyword>
	<keyword>safety</keyword>
	<keyword>splenectomy</keyword>
	<keyword>serum sickness</keyword>
</DOC>